Findings from an analysis of nearly a million data points comprising 1000 KOLs across 12 therapy areas.
Which quantitative metrics/characteristics correlate most closely with “KOL status”?
Disparity between qualitative & quantitative metrics: Does Qual add anything beyond the Quant?
What about identifying specific KOL subgroups? e.g. Digital KOLs,Rising stars & Orphan diseases.
How to apply this research to create in-house protocols for firstpass identification and validation of KOLs, easily and quickly?
Speaker
Sanjay Singhvi
Director, System Analytic, UK
REMINDER
This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of Evidence Life Science.